Session Type: Abstract Submissions (ACR)
Background/Purpose: Backgrounds: This study was performed to prospectively and independently validate the GAPSS (1) (Global APS Score), a score system derived from the combination of independent risk factors for thrombosis, taking into account the antiphospholipid antibodies (aPL) profile and the conventional cardiovascular risk factors.
GAPSS were prospectively applied to 52 consecutive SLE patients with positive aPL (51 female, mean age 39.1±10.6, mean follow-up 47.53±19.15 months). GAPSS scoring system was calculated yearly for each patient by adding together the points corresponding to the risk factors.
An increase in the GAPSS (entry Vs. last visit) was seen in patients who experienced thrombosis (n=5, 6±5.05 Vs 9.4±4.93, p=0.0388). No changes were observed in those without thrombotic event (n=47, 8.28±4.88 Vs 7.13±5.75, p= NS).
An increase of more than 3 points in GAPSS during the follow-up was strongly associated with higher risk of thrombosis (HR 25.00 [95%IC 3.74-189.1]). The risk of thrombosis was also evaluated by Kaplan-Meier analysis (fig.1; IE: ischemic event) and the cumulative proportion of thrombosis-free individuals was higher (p=0.002) in the patients whose GAPSS was not increased by 3 or more points.
We have prospectively demonstrated that GAPSS is a valid tool for accurate prediction of thrombosis in SLE patients with aPL.
1. GAPSS: the Global Anti-Phospholipid Syndrome Score. Rheumatology (Oxford). 2013 Jan 12. [Epub ahead of print]
M. J. Cuadrado,
M. A. Khamashta,
M. L. Bertolaccini,
« Back to 2013 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/prospective-validation-of-the-global-antiphospholipid-syndrome-score-gapss/